Pharmacology News

Results from a phase 1B/2A trial showed that a long-acting glycopegylated fibroblast growth factor 21 analog reduced liver fat and triglycerides in adults with nonalcoholic steatohepatitis. It was the top story in endocrinology last week.

Patients with valvular atrial fibrillation who recently began using direct oral anticoagulants had a lower risk for systemic embolism or ischemic stroke and major bleeding compared with new warfarin users, an analysis showed.

An increased incidence of venous thromboembolism, or VTE, among patients with COVID-19 has been observed since the early days of the pandemic.

Triple combination therapy with bempedoic acid, ezetimibe and atorvastatin significantly reduced LDL among patients with hypercholesterolemia, researchers reported.

Beta-blockers were not associated with depression and other psychiatric adverse events, although they may have a relationship with sleep disorders, according to a meta-analysis.

Over time, people with HIV who received Vemlidy instead of Viread as part of their antiretroviral therapy experienced weight gain and other negative metabolic changes, researchers reported in Annals of Internal Medicine.

Adults with obesity who continued once-weekly semaglutide therapy beyond 20 weeks saw continued weight loss or weight maintenance compared with adults who were switched to placebo, data from the STEP 4 study show.

About half of the first-year positions that were offered in the 2021 Main Residency Match were in primary care, family medicine, internal medicine and pediatrics, and most of these positions have been filled, according to the National Resident Matching Program.

Many older adults do not recognize potential adverse events associated with their new medications, according to a study published in the Journal of General Internal Medicine.

An app can help patients with chronic pain improve their anxiety and pain catastrophizing, according to research published in JMIR mHealth.